Ajanta Pharma Share Price
3488.80-32.30 (-0.92%)
+36.41% past 1 Year
Ajanta Pharma is a specialty pharmaceutical company engaged in development, manufacturing and marketing of quality finished dosages. Its business includes Branded Generics in emerging markets of Asia and Africa, Generics
Corporate filings & documents
Announcements
Pls find enclosed Intimation w.r.t Participation in Investor Conference.
4 days agoPls find enclosed Intimation w.r.t Participation in Investor Conference.
4 days agoPls find enclosed newspaper publication for transfer of equity shares to IEPF.
4 days agoPls find enclosed newspaper publication for transfer of equity shares to IEPF.
4 days agoThe Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 on August 27 2026 for Aayush Agrawal trustee Aayush Agrawal Trust
1 week agoThe Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 on August 27 2026 for Aayush Agrawal trustee Aayush Agrawal Trust
1 week agoThe Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 on August 19 2026 for Ravi Agrawal trustee Ravi Agrawal Trust
2 weeks agoThe Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 on August 19 2026 for Ravi Agrawal trustee Ravi Agrawal Trust
2 weeks agoThe Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 on August 14 2026 for Ravi Agrawal trustee Ravi Agrawal Trust
3 weeks agoThe Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 on August 14 2026 for Ravi Agrawal trustee Ravi Agrawal Trust
3 weeks agoPls find enclosed Intimation w.r.t participation in Investor Conference
4 weeks agoPls find enclosed Intimation w.r.t participation in Investor Conference
4 weeks agoPls find enclosed herewith Earning Call Transcript
1 month agoPls find enclosed herewith Earning Call Transcript
1 month agoPls find enclosed newspaper publication of financial results for the quarter ended 30.06.2026.
1 month agoPls find enclosed newspaper publication of financial results for the quarter ended 30.06.2026.
1 month agoPls find enclosed Audio Recording of Earnings Call
1 month agoPls find enclosed Audio Recording of Earnings Call
1 month agoPls find enclosed ESOP Allotment
1 month agoPls find enclosed ESOP Allotment
1 month agoPFA record date intimation
1 month agoPFA record date intimation
1 month agoPFA Dividend Intimation
1 month agoPFA Dividend Intimation
1 month agoResults of 30.06.2026.
1 month agoResults of 30.06.2026.
1 month agoBoard Meeting Outcome
1 month agoBoard Meeting Outcome
1 month agoThe Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 on July 29 2026 for Aayush Agrawal trustee Aayush Agrawal Trust
1 month agoThe Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 on July 29 2026 for Aayush Agrawal trustee Aayush Agrawal Trust
1 month agoPls find enclosed Revised Investor Call Intimation
1 month agoPls find enclosed Revised Investor Call Intimation
1 month agoPls fine enclosed Investor Call Intimation
1 month agoPls fine enclosed Investor Call Intimation
1 month agoAjanta Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/07/2026 inter alia to consider and approve Update on board meeting
1 month agoAjanta Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/07/2026 inter alia to consider and approve Update on board meeting
1 month agoAjanta Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/07/2026 inter alia to consider and approve Financial Results for the quarter ended 30th June 2026.
1 month agoAjanta Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/07/2026 inter alia to consider and approve Financial Results for the quarter ended 30th June 2026.
1 month agoPls find enclosed voting and scrutinizers report w.r.t to 47th AGM held on 16.07.2026.
1 month agoPls find enclosed voting and scrutinizers report w.r.t to 47th AGM held on 16.07.2026.
1 month agoPls find enclosed AGM Proceedings
1 month agoPls find enclosed AGM Proceedings
1 month agoThe Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 on July 14 2026 for Ravi Agrawal trustee Ravi Agrawal Trust
1 month agoThe Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 on July 14 2026 for Ravi Agrawal trustee Ravi Agrawal Trust
1 month agoThe Exchange has received revised Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 on July 08 2026 for Aayush Agrawal trustee Aayush Agrawal Trust Aayush M Agrawal & Gabs Investments Pvt Ltd
1 month agoThe Exchange has received revised Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 on July 08 2026 for Aayush Agrawal trustee Aayush Agrawal Trust Aayush M Agrawal & Gabs Investments Pvt Ltd
1 month agoPls find enclosed Certificate under Regulation 74(5) of SEBI (DP) Regulations 2018 for the quarter ended 30.06.2026.
1 month agoPls find enclosed Certificate under Regulation 74(5) of SEBI (DP) Regulations 2018 for the quarter ended 30.06.2026.
1 month agoThe Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for CTL Trusteeship Ltd
2 months agoThe Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for CTL Trusteeship Ltd
2 months agoConcalls & investor presentations
Jul 2026
May 2026
Jan 2026
Nov 2025
Jul 2025
ConcallPresentation
Apr 2025
Jan 2025
Oct 2024
Jul 2024
May 2024
Jan 2024
Oct 2023
Jul 2023
May 2023
ConcallPresentation
May 2023
ConcallPresentation
Feb 2023
Nov 2022
Jul 2022
May 2022
Jan 2022
Oct 2021
Jul 2021
Apr 2021
Feb 2021
ConcallPresentation
Nov 2020
ConcallPresentation
Corporate Actions
Date
Type
Details
2026-08-05
Dividend
32.0
2025-11-10
Dividend
28.0
2024-11-06
Dividend
28.0
2024-02-08
Dividend
26.0
2023-08-04
Dividend
15.0
2022-11-11
Dividend
7.0
2022-06-22
Bonus
1:2
2020-11-12
Dividend
9.5
2019-11-15
Dividend
13.0
2018-11-09
Dividend
9.0
2017-03-23
Dividend
7.0
2016-11-07
Dividend
6.0
2016-03-17
Dividend
8.0
2015-06-25
Dividend
6.0
2015-03-20
Split
5:2
2014-07-24
Dividend
10.0
2013-09-17
Bonus
1:2
2013-07-18
Dividend
6.25
2012-08-09
Split
10:5
2012-06-28
Dividend
7.5
2011-06-23
Dividend
5.0
2010-06-29
Dividend
3.5
Company details
Registered office
Ajanta Tower, 54 - A M V Road, Chakala Andheri (East) Mumbai Maharashtra PIN: 400093 Tel No: 022-60609000 / 66061000 Fax No: 022-66061200/300 Email: [email protected] Internet: www.ajantapharma.com
Registrars
C 101, 247 Park, LBS Marg, Vikhroli (W), Mumbai(Old Address:) C-13 Pannalal Silk Compound, L B S Marg, Bhandup Mumbai Maharashtra C 101, 247 Park LBS Marg Vikhroli (West) PIN: Tel No: +91 810 811 8484 Fax No: 91-022-49186060 Email: [email protected] Internet: https://in.mpms.mufg.com/
Management
Gaurang Shah, Sr. VP – Legal & Company Secretary, Compliance Officer
Mannalal B Agrawal, Chairman
Madhusudan B Agrawal, Vice Chairman
Yogesh M Agrawal, Managing Director
Rajesh M Agrawal, Joint Managing Director
David Rasquinha, Non Executive Independent Director
Medha Joshi, Non Executive Independent Director
Rajesh Dalal, Non Executive Independent Director
Simi Thapar, Non Executive Independent Director
Details
BSE 532331
NSE AJANTPHARM
ISIN INE031B01049